Bioporto As Stock Net Income
| THOXF Stock | USD 0.15 0.14 48.28% |
As of the 9th of February, BioPorto shows the Mean Deviation of 1.44, standard deviation of 5.94, and Risk Adjusted Performance of (0.09). In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of BioPorto, as well as the relationship between them. Please confirm BioPorto AS market risk adjusted performance and total risk alpha to decide if BioPorto AS is priced correctly, providing market reflects its regular price of 0.15 per share. As BioPorto AS appears to be a penny stock we also recommend to validate its information ratio numbers.
BioPorto's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing BioPorto's valuation are provided below:BioPorto AS does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. BioPorto |
BioPorto 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BioPorto's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BioPorto.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in BioPorto on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding BioPorto AS or generate 0.0% return on investment in BioPorto over 90 days. BioPorto is related to or competes with Spectral Med, Integrated Diagnostics, Euroapi SA, Clinuvel Pharmaceuticals, Immutep, Northwest Biotherapeutics, and Ion Beam. BioPorto AS, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers wor... More
BioPorto Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BioPorto's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BioPorto AS upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 48.28 |
BioPorto Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioPorto's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BioPorto's standard deviation. In reality, there are many statistical measures that can use BioPorto historical prices to predict the future BioPorto's volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.74) | |||
| Total Risk Alpha | (1.33) | |||
| Treynor Ratio | 26.48 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of BioPorto's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
BioPorto February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | 26.49 | |||
| Mean Deviation | 1.44 | |||
| Coefficient Of Variation | (812.40) | |||
| Standard Deviation | 5.94 | |||
| Variance | 35.31 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.74) | |||
| Total Risk Alpha | (1.33) | |||
| Treynor Ratio | 26.48 | |||
| Maximum Drawdown | 48.28 | |||
| Skewness | (8.12) | |||
| Kurtosis | 66.0 |
BioPorto AS Backtested Returns
BioPorto AS secures Sharpe Ratio (or Efficiency) of -0.13, which signifies that the company had a -0.13 % return per unit of risk over the last 3 months. BioPorto AS exposes eighteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm BioPorto's Risk Adjusted Performance of (0.09), standard deviation of 5.94, and Mean Deviation of 1.44 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -0.028, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning BioPorto are expected to decrease at a much lower rate. During the bear market, BioPorto is likely to outperform the market. At this point, BioPorto AS has a negative expected return of -0.77%. Please make sure to confirm BioPorto's jensen alpha and day median price , to decide if BioPorto AS performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.00 |
No correlation between past and present
BioPorto AS has no correlation between past and present. Overlapping area represents the amount of predictability between BioPorto time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BioPorto AS price movement. The serial correlation of 0.0 indicates that just 0.0% of current BioPorto price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | -0.15 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, BioPorto AS reported net income of (57.11 Million). This is 116.73% lower than that of the Healthcare sector and 132.99% lower than that of the Diagnostics & Research industry. The net income for all United States stocks is 110.0% higher than that of the company.
BioPorto Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioPorto's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BioPorto could also be used in its relative valuation, which is a method of valuing BioPorto by comparing valuation metrics of similar companies.BioPorto is currently under evaluation in net income category among its peers.
BioPorto Fundamentals
| Return On Equity | -0.88 | |||
| Return On Asset | -0.41 | |||
| Profit Margin | (2.50) % | |||
| Operating Margin | (2.82) % | |||
| Current Valuation | 106.91 M | |||
| Shares Outstanding | 334.68 M | |||
| Shares Owned By Insiders | 19.84 % | |||
| Shares Owned By Institutions | 8.60 % | |||
| Price To Book | 12.43 X | |||
| Price To Sales | 9.27 X | |||
| Revenue | 24.25 M | |||
| Gross Profit | 15.04 M | |||
| EBITDA | (58.6 M) | |||
| Net Income | (57.11 M) | |||
| Cash And Equivalents | 86.72 M | |||
| Cash Per Share | 0.32 X | |||
| Total Debt | 10.42 M | |||
| Debt To Equity | 0.12 % | |||
| Current Ratio | 4.03 X | |||
| Book Value Per Share | 0.27 X | |||
| Cash Flow From Operations | (64.58 M) | |||
| Earnings Per Share | (0.03) X | |||
| Number Of Employees | 31 | |||
| Beta | 1.49 | |||
| Market Capitalization | 121.23 M | |||
| Total Asset | 81.25 M | |||
| Z Score | 6.6 | |||
| Net Asset | 81.25 M |
About BioPorto Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioPorto AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioPorto using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioPorto AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in BioPorto Pink Sheet
BioPorto financial ratios help investors to determine whether BioPorto Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioPorto with respect to the benefits of owning BioPorto security.